Archives
- 2026-11
- 2026-10
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
Stat3 Mediates Fyn-Driven Dopaminergic Neurodegeneration
2026-09-17
This zebrafish study identifies Stat3 as a downstream effector linking constitutively active Fyn kinase to dopaminergic neuron loss, mitochondrial abnormalities, and microglial inflammation. Its combination of cell-type-specific genetics, live imaging, transcriptomics, and pathway inhibition provides a useful mechanistic framework for Parkinson’s disease research while highlighting important limits in translating larval zebrafish findings to mammalian disease.
E-64d as a Probe of Lysosomal Protease Death
2026-09-17
E-64d is a membrane-permeable cysteine protease inhibitor that can dissect calpain and cathepsin contributions to intracellular cell death. This article connects E-64d assay design with the lysoptosis framework, emphasizing how to distinguish protease dependence from lysosomal membrane damage.
Fucoidan, the Gut–Liver Axis, and Chemotherapy Injury
2026-09-16
A 2026 International Immunopharmacology study identifies intestinal barrier failure and neutrophil extracellular trap accumulation as linked drivers of irinotecan-induced steatohepatitis. The work shows that Fucoidan can reduce this gut–liver inflammatory sequence by preserving tight junction integrity, limiting lipopolysaccharide translocation, partially reshaping gut microbiota, and suppressing hepatic NETs.
Thioredoxin 1 and Late-Stage Lens Iron Recovery
2026-09-16
This preprint identifies thioredoxin 1 (Trx1) as a potential regulator of late-stage recovery from oxidative damage and iron imbalance in the lens, with ferritin heavy chain (FTH1) implicated as a downstream mediator. Its staged in vivo and in vitro design suggests that age-related cataract biology is temporally dynamic, although the proposed Trx1–FTH1 pathway requires validation in peer-reviewed and clinically relevant models.
EZ Cap™ Mouse CD252(OX40L) mRNA: Assay Strategy
2026-09-15
Explore how EZ Cap™ Mouse CD252(OX40L) mRNA (m1Ψ, HA tag) can support mechanistic immune co-stimulation studies. This guide distinguishes OX40L-specific assay design from related mRNA vaccine evidence and translates the literature into practical controls and readouts.
EGTA and Calcium Flux: From Channel Biology to Translation
2026-09-15
EGTA, or egtazic acid, offers translational researchers a practical way to interrogate calcium-dependent injury without confusing calcium availability with channel subtype activity. This article connects calcium chelation to neuroprotection, cardiac vagal physiology, assay design, and more disciplined model selection.
Fucoidan Workflows for Breast Cancer Research
2026-09-14
Build reproducible Fucoidan assays around MCF-7 cytotoxicity, migration, colony formation, and caveolin-1 analysis. This workflow also shows how to connect breast cancer findings with apoptosis, angiogenesis, and immune-modulation studies without overextending the evidence.
17-AAG (Tanespimycin): Reliable Cell Assays
2026-09-14
A scenario-based guide to improving viability, proliferation, and cytotoxicity experiments with 17-AAG (Tanespimycin), SKU A4054. It connects HSP90 biology with formulation control, dose-response design, endpoint interpretation, and practical product selection for reproducible cancer research.
GW 4869: Exosome Workflow for Lupus Nephritis
2026-09-13
GW 4869 hydrochloride hydrate provides a practical pharmacologic gate for testing whether neutral sphingomyelinase-dependent vesicle release drives endothelial injury. This workflow combines donor-cell perturbation, extracellular vesicle normalization, HMGB1/TRIM27 pathway testing, and controls that distinguish exosome effects from broader sphingolipid signaling.
Necrostatin 2 (Nec-2) Workflow for Necroptosis
2026-09-12
Necrostatin 2 (Nec-2) provides a temporally controlled way to investigate programmed necrotic cell death, RIPK2 signaling, and membrane-injury phenotypes. This practical guide connects Nec-2 dose optimization with the Kupffer-cell and plasma-membrane findings reported in Listeria research, while clearly separating established evidence from exploratory applications.
Blebbistatin for Causal Cell Mechanics Imaging
2026-09-11
Use (±)-Blebbistatin to connect non-muscle myosin II activity with migration, adhesion, and morphology while preserving a reversible live-cell workflow. Inspired by panoramic cardiac mapping, the approach pairs mechanical perturbation with registered structure–function imaging for stronger causal interpretation.
Neuritin, ER Stress, and NF-κB After SAH
2026-09-11
The reference study identifies coordinated endoplasmic reticulum stress pathways as drivers of NF-κB-linked neuroinflammation and neuronal apoptosis during early brain injury after subarachnoid hemorrhage. Its central contribution is showing that neuritin overexpression suppresses these convergent pathways, providing a mechanistic framework for evaluating neuroprotective interventions in SAH.
Native-Membrane Proteoforms and Drug Selectivity
2026-09-10
A 2025 Nature Chemistry study introduces native top-down mass spectrometry for connecting membrane-protein modifications with ligand interactions in intact lipid environments. Using retinal rhodopsin, G proteins, and PDE6, the authors show that proteoform identity and lipidation can shape drug binding and off-target selectivity.
Native Proteoform Interactions for Drug Targeting
2026-09-10
This Nature Chemistry study introduces native top-down mass spectrometry for resolving membrane-protein proteoforms and their ligand interactions without first removing the native lipid environment. Its analysis of rhodopsin, G-protein lipidation, and PDE6 binding by Vardenafil and sildenafil shows why modification-resolved pharmacology can reveal off-target behavior missed by conventional assays.
Vardenafil HCl Trihydrate in PDE5 Research
2026-09-09
Vardenafil HCl Trihydrate gives researchers a high-potency, selective tool for connecting PDE5 inhibition with cGMP signaling, smooth muscle relaxation, and functional erectile dysfunction models. Its use can be extended into proteoform-aware workflows that compare soluble enzyme assays with native membrane and PDE6 counter-screening.
8050 records 8/537 page Previous Next First page 上5页 678910 下5页 Last page